Company: OSRH
Filing Date: 2025-01-24
Form Type: S-4/A
Source: 0001213900-25-006139
Chunk: 250

Company: OSR Holdings, Inc.
Filing Date: 2025-01-24
Form: S-4/A
Chunk 250
---
 business partner, to arrange for an in -personmeeting at BLAC/OSR Holdings’ offices in Seoul. Investor A proposed to bring another colleague from a manufacturing partner to the meeting. Investor A told Mr. Whang that such company would become Company B’s manufacturing partner for product distribution in Korea. Upon conducting initial due diligence and background checks, it was discovered that a key individual from the potential manufacturing partner was involved (as of April 2023) in litigation. Subsequently, BLAC decided not to pursue further discussions with Company B. Company C On March 21, 2023, BLAC received an unsolicited email from the Chief Business Officer of another potential target company of BLAC (“Company C”), inquiring about business combination opportunities that BLAC was considering. Company C is a clinical stage immune -oncologycompany with two broadly applicable platform technologies involving CAR -CIKAutologous RNA loaded dendritic cells. The Chief Business Officer of Company C wrote he had seen an announcement of BLAC’s recent listing on Nasdaq. By email dated April 13, 2023, Company C sent BLAC its non -confidentialcompany presentation. The presentation was circulated internally at BLAC and OSR Holdings for review. By email dated April 24, 2023, Mr. Hwang inquired about Company C’s technology and asked for a mutually convenient time for a video conference. On April 28, 2023, officers of Company C, BLAC (Messrs. Hwang and Whang), OSR Holdings (Sung Hoon Chung and Dr. Senyeon Choe), Dr. Pan, and Mr. Shin, participated in a video conference. Mr. Hwang began by explaining that currently, BLAC was considering an affiliated transaction with OSR Holdings, that OSR Holdings was considering acquiring additional portfolio companies, and that any acquisition of Company C would have to be via acquisition by OSR Holdings. Company C’s Chief Business Officer said Company C was only considering a direct business combination with a SPAC. There were no further communications with Company C. Company D Another potential target company (“Company D”) was introduced to former OSR Holdings Managing Director Sung Hoon Chung’s former colleague at Auerbach Grayson (“Broker”) on March 23, 2023. Company D is a clinical stage biotech company with a pipeline of three clinical trials on Glioblastoma Multifore (“GBM”). On March 23, 2023, Broker circulated a non -